Parnell Launches First FDA-Approved Generic Florfenicol + Flunixin for BRD

Got story updates? Submit your updates here. ›

Parnell Pharmaceuticals has announced the launch of nixiFLOR®, the first FDA-approved generic combination of the antibacterial florfenicol and the anti-inflammatory flunixin for the treatment of bovine respiratory disease (BRD) in cattle. The new product provides veterinarians with a more affordable alternative to the branded version while maintaining the same active ingredients and efficacy.

Why it matters

Bovine respiratory disease is a leading cause of illness and death in cattle, costing the industry billions annually. Having access to more cost-effective treatment options can help improve herd health and reduce economic losses for cattle producers.

The details

nixiFLOR® contains the same active pharmaceutical ingredients as the branded combination product - florfenicol, an antibacterial, and flunixin, an anti-inflammatory. The new generic version is designed to provide the same therapeutic benefits at a lower cost. Parnell received FDA approval for nixiFLOR® after demonstrating bioequivalence to the reference product.

• nixiFLOR® received FDA approval on April 1, 2026.
• The product is now available for purchase by veterinarians and cattle producers.

What they’re saying